Corporate Presentation
43rd Annual J.P. Morgan Healthcare Conference
Tony He (hexiang@3sbio.com)
Chief Financial Officer
January 16th, 2025
San Francisco, California
01. Overview
3
Over Three Decades of Excellence and Continuous Innovation
Interfen®
（interferon α-2ª）
Inleusin®
(IL-2)
BCG-PSN®
(BCG Polysaccharide and
Nucleic Acid injection)
EPIAO®
（rhEPO）
Mandi®
（Minoxidil）
SEPO®
（rhEPO）
SPARIN®
(low molecular-weight
heparin calcium)
TPIAO®
（rhTPO）
Yisaipu®
(rhTNFR-Fc)
IV Sucrose®
(Iron sulcrose)
Qiming Keli®
（Diabetic
retinopathy）
Xenopax®
(Recombinant
humanized anti-
CD25 mab)
Byetta®
(Exenatide
Injection)
Cipterbin®
（Inetetamab
anti-HER2 mAb）
YSP ®
(Pre-filled injection)
Remitch®
(Narfuraphine
hydrochloride orally disintegrating tablets)
Mandi®
（Minoxidil
Foam）
TeAiSheng®
（Eltrombopag for Oral Suspension）
1993 | 1995 | 1996 | 1998 |
2001
2005 | 2006 | 2007 | 2009 | |
2002 | ||||
2024
2016 2017 | 2020 | 2023 | ||||
2014 | 2015 | |||||
2013 | ||||||
2011 | ||||||
Established main subsidiary Shenyang Sunshine co.,
The first IPO of Chinese biopharmaceutical company in
NASDAQ
Privatized by a consortium led by management and CPE and delisted from Nasdaq
Acquired Sciprogen co., and Sirton (Italy)
Became the third largest shareholder of CITI-guojian and signed strategic cooperation agreement
Listed on HKEX (1530.HK)
Acquired Zhejiang Wansheng
Included in
Hang Seng
Composite
LargeCap &
MidCap Index
Increased Guojian's share proportion to 97.8%
Partnered with AZ for Ⅱ diabetes drugs
TPIAO, Yisaipu listed in 2017 NRDL
Partnered with Lilly for Exenatide
Funded €300M
through convertible bond
Sunshine-guojian listed on SSE Star Board (688366)
Redeemed €300M convertible bond
Obtained IFC granting＄200mn
equivalents long- term low-interest loan credit
4
Where We Are Today
24.5% | 28 | >50 | 42nd | ||||||||||||||
2013-2023 Revenue CAGR | Disclosed R&D Pipelines | 7 | Approved Products | ||||||||||||||
China's Top 100 Pharma by | |||||||||||||||||
Facilities Globally | |||||||||||||||||
Overall Industry Capability | |||||||||||||||||
￥7.8 Bn | ~700 | ~3,000 | |||||||||||||||
Revenue in 2023 | R&D Staffs | Commercialization | |||||||||||||||
>4.5% | Professionals | AA | |||||||||||||||
20+ | |||||||||||||||||
￥7.9 Bn | >10% | Dividend Yield at | MSCI ESG Rating | ||||||||||||||
Current Valuation | for Three Consecutive Years | ||||||||||||||||
Financial Resources | R&D as a % of Revenue | Countries Worldwide | |||||||||||||||
5
Consistent Track Record of Annual Growth for Over a Decade
TPO | Mandi | rhEPO | YSP | Others | 7.8bn | |||||||||||||
10 yrs CAGR 24.5% | ||||||||||||||||||
6.9bn | ||||||||||||||||||
6.4bn | 7% | |||||||||||||||||
5.6bn | ||||||||||||||||||
5.3bn | 12% | |||||||||||||||||
9% | ||||||||||||||||||
4.6bn | 12% | 16% | 14% | |||||||||||||||
11% | ||||||||||||||||||
3.8bn | 18% | |||||||||||||||||
22% | 13% | |||||||||||||||||
17% | ||||||||||||||||||
2.8bn | 24% | 9% | ||||||||||||||||
14% | 7% | |||||||||||||||||
1.7bn | 27% | 20% | 54% | |||||||||||||||
28% | ||||||||||||||||||
49% | ||||||||||||||||||
0.9bn | 1.1bn | 23% | 49% | 48% | ||||||||||||||
28% | 44% | |||||||||||||||||
43% | ||||||||||||||||||
36% | ||||||||||||||||||
54% | 52% | |||||||||||||||||
26% | ||||||||||||||||||
36% | 27% | |||||||||||||||||
39% | ||||||||||||||||||
35% | ||||||||||||||||||
2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
6
Milestones in 2024
Oncology / Hematology
- rhTPO showed various studies in APASL for its applications in HRT and benefits in liver function improvement
• | TPIAO® pediatric | • | rhTPO was |
ITP approved by | recommended by | ||
CDE | the Guide1 for | ||
• | Phase II | CLDT treatment | |
enrollment of | • | FPI under Phase II | |
PD1/VEGF | of PD1/VEGF | ||
commenced | |||
• | TPIAO® was |
recommended by | |
the Guide2 for TCP | |
treatment after | |
kidney transplant | |
• | Inetetamab's several |
studies were | |
selected by 2024 |
• TPIAO® NDA for |
CLDT accepted |
for review by |
CDE |
• Inetetamab's | • Exclusive |
several studies | commerciali- |
were selected in | zation rights |
2024 ESMO, | of Paclitaxel |
showing its safety | Oral Solution |
and effectiveness in |
Neoadjuvant breast cancer treatment
• | Exclusive |
commercialization | |
rights of Clifutinib | |
besylate | |
• | Strategic partnership |
in a natural killer cell | |
production technology | |
platform |
• TeAiSheng® |
launched as the 1st |
Eltrombopag for |
Oral Suspension in |
China |
Nephrology
• Long-acting | • | Remitch® |
rESP (SSS06)'s | ||
successfully held | ||
phase III trial | ||
the first commercial | ||
met primary | ||
listing ceremony | ||
endpoints | ||
ASCO, showing its |
safety and |
effectiveness |
• Long-acting |
rESP (SSS06) |
NDA accepted |
for review by |
CDE |
• Investment in C-Ray, |
a radiopharmaceutical |
biotech |
• | TPIAO and Inetetamab |
renewed with NRDL at | |
current terms | |
• | Remitch® covered by |
NRDL for dialysis pruritus |
Feb. | Apr. | Jun. | Aug. | Oct. | Dec. | |
Jan. | Mar. | May | Jul. | Sep. | Nov. | |
Autoimmune
Dermatology
- Consumer Health
- Tacrolimus ointment launched
- Anti-IL-5mAb(610) phase II trial in eosinophilic asthma met primary endpoints
- Anti-IL-4RmAb(611) phase III trial in adult AD completed FPI
- Anti-IL-1βmAb (613) phase III in acute gout completed FPI
• Consumer | • Obtained the license of |
health | Semaglutide (weight |
subsidiary | management) |
rebranded as Sunshine mandi
- Anti-IL-4RmAb(611) phase II trial in CRSwNP met primary endpoints
- Anti-IL-17AmAb(608) phase III trial in moderate- to-severePsO accomplished
• Anti-BDCA2 mAb(626) | • | Anti-IL-17A | • Anti-TL1A | ||||
IND application in SLE | mAb(608) NDA for | mAb(627) IND | |||||
and CLE approved by | moderate-to-severe | application | |||||
CDE and FDA | PsO accepted for | submitted | |||||
review by CDE | |||||||
• | Mandi ranked the 1st place in | ||||||
Tmall, JD pharmacy, Tiktok | |||||||
shop 's lists | |||||||
• | Winlevi® bridging trial in | acne | |||||
vulgaris completed enrollment | |||||||
7 1. "Standard for diagnosis and treatment of primary liver cancer (2024 edition)"
2. "Clinical diagnosis and treatment guidelines for long-term systemic complications in kidney transplant recipients in China"
Strong Financial Performance
Revenue | Gross Profit | Attributable Profits | Financial Resources | |||||||||||
16.0% YOY | 18.6% YOY | 11.1% YOY | 7.9 Bn | |||||||||||
Bn | Gross margin 86.5% | Bn | Bn | Bn | ||||||||||
7.8 | ||||||||||||||
6.9 | 6.6 | 7.9 | ||||||||||||
8.2 | ||||||||||||||
6.4 | 5.7 | 1.92 | 7.4 | |||||||||||
5.3 | 1.65 | |||||||||||||
1.55 | ||||||||||||||
4.4 | 3.8 | |||||||||||||
3.8 | 1.09 | |||||||||||||
3.2 | 0.98 | 5.0 | ||||||||||||
4.5 | ||||||||||||||
2021 | 2022 | 2023 | 2023H1 2024H1 | 2021 | 2022 | 2023 | 2023H1 2024H1 | 2021 | 2022 | 2023 | 2023H1 2024H1 |
8
Globally Recognized Commercialization Professionals
Proven marketing team with over 30 years of recognition
Covers all provinces, autonomous regions and special municipalities in China
c.3,000 sales and marketing employees
Covers c.2,900 Grade III hospitals
Covers 6,800+ Grade II or lower ranking hospitals and medical institutions
Tens of millions of online customers
- Various 3SBio's products have been approved overseas, including TPIAO, Yisaipu, EPIAO, SEPO, etc.
- The registration has covered nearly 40 countries and regions around the world, with the business and customer scope basically covering all the developing countries
EPIAO (rhEPO) | TPIAO (rhTPO) |
Marketed in 24 countries | Marketed in 9 countries including |
including Philippines, Brazil, Thailand, | Uzbekistan, Thailand, Philippines…… |
Colombia, Egypt…… |
YSP (Etanercept) | Cipterbin (anti-HER2 mAb) |
Marketed in 16 countries | Marketed in 3 countries |
including Indonesia, Mexico, Thailand…… | including Egypt, Morocco, Philippines |
9
Comprehensive Manufacturing Capabilities
7 plants worldwide with high manufacturing capacity supplying both development and commercialization
1500+ production professionals
Established manufacturing and R&D facilities in Shenyang, Shanghai, Hangzhou, Shenzhen, Dongguan and Italy
Shenyang - Biologics | Shanghai - Biologics | Shenzhen - | Dongguan - CGT / mRNA | Hangzhou - Chemicals | Como, Italy - CDMO | |
Biologics/Chemicals | ||||||
10
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |